Market Access Dashboard

Total Payers
6
Total Plans
12
Avg Approval Rate
71.2%
Avg Denial Rate
28.8%
Active Alerts
5
Unack'd High Severity
2
Total Playbooks
5
Total Policy Docs
10
Denial Trend (Last 6 Months)
  • Avoidable
  • Total Denials
2026-012026-012026-012026-022026-022026-022026-032026-032026-032026-042026-0401234
Formulary Coverage Distribution
  • non preferred
  • preferred
  • prior auth required
  • specialty
8442
Payer Risk Index
Centene
72.4
Aetna
68.3
Blue Cross Blue Shield
58.9
Cigna
55.1
UnitedHealthcare
42.5
Humana
32.8
Top Access Barriers
036912formulary exclusionstep therapymissing documentationbenefit limitationmedical necessity
Recent Unacknowledged Alerts
Event TypeDescriptionSeverityDate
formulary_changeAetna moved Keytrevala from Tier 3 to Tier 4 (non-preferred) effective March 2025HIGHApr 13, 2026
new_restrictionBCBS added 3-step therapy requirement for biologic drugs in rheumatologyHIGHApr 13, 2026
pa_criteria_updateCentene simplified Medicaid PA requirements — reduced required documents from 5 to 3LOWApr 13, 2026
new_restrictionAetna added quantity limit for infusion drugs: max 4 infusions per 28-day cycleMEDIUMApr 13, 2026
tier_changeCigna moved Keytruda from Tier 5 to Tier 4 for select indicationsMEDIUMApr 13, 2026